"AquAdvantage salmon" is a genetically modified (GM) Atlantic salmon developed by AquaBounty Technologies. It grows much faster than its farmed non-GE or wild counterparts by containing a gene encoding Chinook salmon growth hormone under the control of an antifreeze protein promoter and terminator from ocean pout [11, 12]. The debates regarding its approval as a species that can be commercialized — it has been dubbed Frankenfish by its opponents — began in September 2011 with a meeting of the Veterinary Medicine Advisory Committee (VMAC) as well as a public hearing, together with the release of a health and safety briefing and an environmental assessment package on the transgenic animal developed by AquaBounty Technologies of Waltham, Massachusetts. Despite VMAC’s determination that AquAdvantage salmon is “as safe as food from conventional Atlantic salmon,” critics continue to raise concerns relating to its allergenicity, levels of insulin-like growth factor 1 (IGF-1) and composition of polyunsaturated fatty acids as well as the potential impacts of the farmed GMO fish on the environment. This development has resulted in various concerns and debates about its safety, health and environmental impacts both in US and Canada, including the regulatory regimes in both countries and their markets .